IRWD
HealthcareIronwood Pharmaceuticals, Inc.
$3.35-0.03 (-0.74%)
Prev Close
$3.38
Open
$3.40
High
$3.51
Low
$3.34
Volume
968.3K
Market Cap
$594.3M
P/E
25.81
Div Yield
—
Over the past 12 months, insider activity at Ironwood Pharmaceuticals, Inc. (IRWD) has been exclusively selling, with 0 insider purchases totaling $0.00 and 15 insider sales totaling $1.62M. The most recent insider transaction was by Gaskins Tammi L (officer: Chief Commercial Officer), who sold $80.3K worth of shares on Feb 25, 2026. Ironwood Pharmaceuticals, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry, with a market cap of $594.3M.
Buys (12M)
0
$0.00
Sells (12M)
15
$1.62M
Net Activity
Net Seller
$1.62M
Active Insiders
6
last 12 mo
IRWD Price Chart
IRWD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 25, 2026↗ | Gaskins Tammi L | officer: Chief Commercial Officer | Sell | 21,526 | $3.73 | $80.3K | 224,977 |
| Feb 25, 2026↗ | John Minardo | officer: Chief Legal Officer | Sell | 36,492 | $3.73 | $136.2K | 382,939 |
| Feb 25, 2026↗ | Martini Gregory S. | officer: Chief Financial Officer | Sell | 21,944 | $3.73 | $81.9K | 172,058 |
| Feb 25, 2026↗ | MCCOURT Thomas A | director, officer: Chief Executive Officer | Sell | 198,283 | $3.73 | $739.9K | 1,592,530 |
| Feb 25, 2026↗ | Shetzline Michael | officer: SVP, CMO, Head-Res&Drug | Sell | 32,582 | $3.73 | $121.6K | 538,437 |
| Feb 25, 2026↗ | Silver Ronald | officer: Principal Accounting Officer | Sell | 24,173 | $3.73 | $90.2K | 265,257 |
| Jan 7, 2026↗ | Silver Ronald | officer: Principal Accounting Officer | Sell | 35,416 | $4.60 | $162.9K | 276,809 |
| Jan 5, 2026↗ | Silver Ronald | Principal Accounting Officer | Sell | 35,416 | $4.60 | $162.9K | 0 |
| Nov 17, 2025↗ | Gaskins Tammi L | Chief Commercial Officer | Sell | 6,016 | $3.32 | $20.0K | 0 |
| Aug 11, 2025↗ | Gaskins Tammi L | Chief Commercial Officer | Sell | 1,316 | $0.84 | $1.1K | 0 |
| Aug 11, 2025↗ | John Minardo | Chief Legal Officer | Sell | 7,754 | $0.84 | $6.5K | 0 |
| Aug 11, 2025↗ | Martini Gregory S. | Chief Financial Officer | Sell | 1,265 | $0.84 | $1.1K | 0 |
| Aug 11, 2025↗ | Silver Ronald | Principal Accounting Officer | Sell | 2,846 | $0.84 | $2.4K | 0 |
| May 16, 2025↗ | Gaskins Tammi L | Chief Commercial Officer | Sell | 2,563 | $0.58 | $1.5K | 0 |
| May 16, 2025↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 13,353 | $0.58 | $7.7K | 0 |
| Feb 12, 2025↗ | John Minardo | Chief Legal Officer | Sell | 38,938 | $1.76 | $68.5K | 408,132 |
| Feb 12, 2025↗ | Martini Gregory S. | Chief Financial Officer | Sell | 12,052 | $1.76 | $21.2K | 183,810 |
| Feb 12, 2025↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 139,064 | $1.76 | $244.8K | 1,160,630 |
| Feb 12, 2025↗ | Shetzline Michael | SVP, CMO, Head-Res&Drug | Sell | 41,269 | $1.76 | $72.6K | 554,007 |
| Feb 12, 2025↗ | Silver Ronald | Principal Accounting Officer | Sell | 12,048 | $1.76 | $21.2K | 279,655 |
| Nov 20, 2024↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 5,360 | $4.08 | $21.9K | 284,685 |
| Nov 20, 2024↗ | Emany Sravan Kumar | SVP, COO and CFO | Sell | 11,001 | $4.08 | $44.9K | 309,572 |
| Aug 14, 2024↗ | John Minardo | Chief Legal Officer | Sell | 9,910 | $4.27 | $42.3K | 284,661 |
| Aug 14, 2024↗ | Silver Ronald | Principal Accounting Officer | Sell | 3,107 | $4.27 | $13.3K | 158,370 |
| Jun 12, 2024↗ | McHugh Julie | Sell | 22,766 | $6.29 | $143.2K | 139,528 | |
| Jun 10, 2024↗ | Moukheibir Catherine | Sell | 80,000 | $6.47 | $517.7K | 84,207 | |
| May 22, 2024↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 22,725 | $6.45 | $146.6K | 288,031 |
| May 22, 2024↗ | John Minardo | Chief Legal Officer | Sell | 17,404 | $6.45 | $112.3K | 294,571 |
| May 22, 2024↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 67,618 | $6.45 | $436.1K | 1,150,330 |
| May 22, 2024↗ | Shetzline Michael | CMO,SVP,Head-Res&Drug | Sell | 16,128 | $6.45 | $104.0K | 413,719 |
| Mar 8, 2024↗ | Duane Jon R | Buy | 6,920 | $8.70 | $60.2K | 121,028 | |
| Mar 6, 2024↗ | Emany Sravan Kumar | SVP, Chief Financial Officer | Buy | 10,684 | $9.38 | $100.2K | 301,733 |
| Feb 14, 2024↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 9,846 | $15.24 | $150.1K | 208,324 |
| Feb 14, 2024↗ | John Minardo | Chief Legal Officer | Sell | 47,380 | $15.24 | $722.1K | 224,796 |
| Feb 14, 2024↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 177,164 | $15.24 | $2.70M | 832,774 |
| Feb 14, 2024↗ | Shetzline Michael | CMO,SVP,Head-Res&Drug | Sell | 38,618 | $15.24 | $588.5K | 340,484 |
| Feb 14, 2024↗ | Silver Ronald | Principal Accounting Officer | Sell | 7,908 | $15.24 | $120.5K | 134,264 |
| Dec 18, 2023↗ | Kessler Marla L | Director | Sell | 9,926 | $11.19 | $111.1K | 96,572 |
| Nov 22, 2023↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 3,287 | $9.69 | $31.9K | 217,374 |
| Sep 18, 2023↗ | Emany Sravan Kumar | SVP, Chief Financial Officer | Buy | 36,072 | $8.32 | $300.1K | 188,730 |
| Aug 16, 2023↗ | John Minardo | Chief Legal Officer | Sell | 7,045 | $10.04 | $70.7K | 192,195 |
| Aug 16, 2023↗ | Silver Ronald | Principal Accounting Officer | Sell | 1,976 | $10.04 | $19.8K | 134,172 |
| Jun 1, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 26,632 | $10.70 | $285.0K | 758,284 |
| May 24, 2023↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 6,305 | $10.12 | $63.8K | 219,327 |
| May 24, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 36,000 | $10.12 | $364.3K | 784,916 |
| May 24, 2023↗ | Shetzline Michael | CMO,SVP,Head-Res&Drug | Sell | 10,324 | $10.12 | $104.5K | 321,131 |
| May 10, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 21,148 | $10.62 | $224.6K | 820,916 |
| Mar 29, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 46,129 | $10.67 | $492.2K | 842,064 |
| Mar 7, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 33,756 | $11.22 | $378.7K | 647,598 |
| Mar 1, 2023↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 3,573 | $11.36 | $40.6K | 153,218 |
IRWD Insider Buying Activity
The following table shows recent insider purchases of Ironwood Pharmaceuticals, Inc. (IRWD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 8, 2024↗ | Duane Jon R | Buy | 6,920 | $8.70 | $60.2K | 121,028 | |
| Mar 6, 2024↗ | Emany Sravan Kumar | SVP, Chief Financial Officer | Buy | 10,684 | $9.38 | $100.2K | 301,733 |
| Sep 18, 2023↗ | Emany Sravan Kumar | SVP, Chief Financial Officer | Buy | 36,072 | $8.32 | $300.1K | 188,730 |
IRWD Insider Selling Activity
The following table shows recent insider sales of Ironwood Pharmaceuticals, Inc. (IRWD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 25, 2026↗ | Gaskins Tammi L | officer: Chief Commercial Officer | Sell | 21,526 | $3.73 | $80.3K | 224,977 |
| Feb 25, 2026↗ | John Minardo | officer: Chief Legal Officer | Sell | 36,492 | $3.73 | $136.2K | 382,939 |
| Feb 25, 2026↗ | Martini Gregory S. | officer: Chief Financial Officer | Sell | 21,944 | $3.73 | $81.9K | 172,058 |
| Feb 25, 2026↗ | MCCOURT Thomas A | director, officer: Chief Executive Officer | Sell | 198,283 | $3.73 | $739.9K | 1,592,530 |
| Feb 25, 2026↗ | Shetzline Michael | officer: SVP, CMO, Head-Res&Drug | Sell | 32,582 | $3.73 | $121.6K | 538,437 |
| Feb 25, 2026↗ | Silver Ronald | officer: Principal Accounting Officer | Sell | 24,173 | $3.73 | $90.2K | 265,257 |
| Jan 7, 2026↗ | Silver Ronald | officer: Principal Accounting Officer | Sell | 35,416 | $4.60 | $162.9K | 276,809 |
| Jan 5, 2026↗ | Silver Ronald | Principal Accounting Officer | Sell | 35,416 | $4.60 | $162.9K | 0 |
| Nov 17, 2025↗ | Gaskins Tammi L | Chief Commercial Officer | Sell | 6,016 | $3.32 | $20.0K | 0 |
| Aug 11, 2025↗ | Gaskins Tammi L | Chief Commercial Officer | Sell | 1,316 | $0.84 | $1.1K | 0 |
| Aug 11, 2025↗ | John Minardo | Chief Legal Officer | Sell | 7,754 | $0.84 | $6.5K | 0 |
| Aug 11, 2025↗ | Martini Gregory S. | Chief Financial Officer | Sell | 1,265 | $0.84 | $1.1K | 0 |
| Aug 11, 2025↗ | Silver Ronald | Principal Accounting Officer | Sell | 2,846 | $0.84 | $2.4K | 0 |
| May 16, 2025↗ | Gaskins Tammi L | Chief Commercial Officer | Sell | 2,563 | $0.58 | $1.5K | 0 |
| May 16, 2025↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 13,353 | $0.58 | $7.7K | 0 |
| Feb 12, 2025↗ | John Minardo | Chief Legal Officer | Sell | 38,938 | $1.76 | $68.5K | 408,132 |
| Feb 12, 2025↗ | Martini Gregory S. | Chief Financial Officer | Sell | 12,052 | $1.76 | $21.2K | 183,810 |
| Feb 12, 2025↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 139,064 | $1.76 | $244.8K | 1,160,630 |
| Feb 12, 2025↗ | Shetzline Michael | SVP, CMO, Head-Res&Drug | Sell | 41,269 | $1.76 | $72.6K | 554,007 |
| Feb 12, 2025↗ | Silver Ronald | Principal Accounting Officer | Sell | 12,048 | $1.76 | $21.2K | 279,655 |
| Nov 20, 2024↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 5,360 | $4.08 | $21.9K | 284,685 |
| Nov 20, 2024↗ | Emany Sravan Kumar | SVP, COO and CFO | Sell | 11,001 | $4.08 | $44.9K | 309,572 |
| Aug 14, 2024↗ | John Minardo | Chief Legal Officer | Sell | 9,910 | $4.27 | $42.3K | 284,661 |
| Aug 14, 2024↗ | Silver Ronald | Principal Accounting Officer | Sell | 3,107 | $4.27 | $13.3K | 158,370 |
| Jun 12, 2024↗ | McHugh Julie | Sell | 22,766 | $6.29 | $143.2K | 139,528 | |
| Jun 10, 2024↗ | Moukheibir Catherine | Sell | 80,000 | $6.47 | $517.7K | 84,207 | |
| May 22, 2024↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 22,725 | $6.45 | $146.6K | 288,031 |
| May 22, 2024↗ | John Minardo | Chief Legal Officer | Sell | 17,404 | $6.45 | $112.3K | 294,571 |
| May 22, 2024↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 67,618 | $6.45 | $436.1K | 1,150,330 |
| May 22, 2024↗ | Shetzline Michael | CMO,SVP,Head-Res&Drug | Sell | 16,128 | $6.45 | $104.0K | 413,719 |
| Feb 14, 2024↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 9,846 | $15.24 | $150.1K | 208,324 |
| Feb 14, 2024↗ | John Minardo | Chief Legal Officer | Sell | 47,380 | $15.24 | $722.1K | 224,796 |
| Feb 14, 2024↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 177,164 | $15.24 | $2.70M | 832,774 |
| Feb 14, 2024↗ | Shetzline Michael | CMO,SVP,Head-Res&Drug | Sell | 38,618 | $15.24 | $588.5K | 340,484 |
| Feb 14, 2024↗ | Silver Ronald | Principal Accounting Officer | Sell | 7,908 | $15.24 | $120.5K | 134,264 |
| Dec 18, 2023↗ | Kessler Marla L | Director | Sell | 9,926 | $11.19 | $111.1K | 96,572 |
| Nov 22, 2023↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 3,287 | $9.69 | $31.9K | 217,374 |
| Aug 16, 2023↗ | John Minardo | Chief Legal Officer | Sell | 7,045 | $10.04 | $70.7K | 192,195 |
| Aug 16, 2023↗ | Silver Ronald | Principal Accounting Officer | Sell | 1,976 | $10.04 | $19.8K | 134,172 |
| Jun 1, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 26,632 | $10.70 | $285.0K | 758,284 |
| May 24, 2023↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 6,305 | $10.12 | $63.8K | 219,327 |
| May 24, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 36,000 | $10.12 | $364.3K | 784,916 |
| May 24, 2023↗ | Shetzline Michael | CMO,SVP,Head-Res&Drug | Sell | 10,324 | $10.12 | $104.5K | 321,131 |
| May 10, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 21,148 | $10.62 | $224.6K | 820,916 |
| Mar 29, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 46,129 | $10.67 | $492.2K | 842,064 |
| Mar 7, 2023↗ | MCCOURT Thomas A | Chief Executive Officer | Sell | 33,756 | $11.22 | $378.7K | 647,598 |
| Mar 1, 2023↗ | Davis Andrew | SVP, Chief Business Officer | Sell | 3,573 | $11.36 | $40.6K | 153,218 |
IRWD Insiders
Similar Stocks to IRWD
ZTS
Zoetis Inc.
$115.50+0.03%
$50.88B
TEVA
Teva Pharmaceutical Industries Limited
$28.41-3.04%
$36.69B
VTRS
Viatris Inc.
$13.51-1.99%
$15.56B
NBIX
Neurocrine Biosciences, Inc.
$129.78+1.29%
$13.03B
INDV
Indivior Pharmaceuticals Inc
$31.32+1.49%
$4.05B
SUPN
Supernus Pharmaceuticals, Inc.
$49.80-1.30%
$3.08B
PAHC
Phibro Animal Health Corporation
$49.52+1.06%
$1.95B
ANIP
ANI Pharmaceuticals, Inc.
$70.32-3.00%
$1.68B